Arrowhead Pharmaceuticals and Sarepta Therapeutics have formed a partnership to develop treatments for rare genetic diseases. The deal includes a substantial upfront payment, equity investment, and potential milestone payments. The collaboration targets rare diseases affecting muscles, lungs, and the central nervous system.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing